Open an account

Annovis Bio

ANVS · NYSE

$0.9783+$0.0183 (+1.91%)TodayMarket closed ·
Prev close $0.96

About ANVS

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). The company is headquartered in Malvern, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2020-01-29. The firm is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.

Employees
8
Headquarters
Malvern, Pennsylvania
Listed
Jan 29, 2020
Sector
Health Care
Industry
Biotechnology
Website
annovisbio.com

ANVS key statistics

Market cap
41.75M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
743.32K
Volume
703.98K
Open price
$0.96
High today
$1.04
Low today
$0.96
52 Week high
$5.50
52 Week low
$0.95

Annovis Bio (ANVS) at a glance

As of Oct 20, 2026, Annovis Bio (ANVS) shares are priced at $0.9783, giving the company a market cap of 41.75M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.96 and $1.04. The current price is 1.9% above the day's low and 5.9% below its high.

Volume so far is 703.98K shares, in line with the average of 743.32K shares a day.

Over the past year Annovis Bio has ranged from $0.95 to $5.50, and now sits 1% of the way up that range.

Annovis Bio met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.40 per share against an estimate of -$0.4624.

The average analyst price target is $10.71, 994.8% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $10.71
Low
$7.07
Now
$0.9783
High
$17.85

ANVS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 15.8% on average.

  1. Q3 FY24: reported -$0.97 per share against an estimate of -$0.5365
  2. Q4 FY24: reported -$0.43 per share against an estimate of -$0.3371
  3. Q1 FY25: reported -$0.32 per share against an estimate of -$0.3635
  4. Q2 FY25: reported -$0.32 per share against an estimate of -$0.4106
  5. Q3 FY25: reported -$0.37 per share against an estimate of -$0.3111
  6. Q4 FY25: reported -$0.39 per share against an estimate of -$0.3502
  7. Q1 FY26: reported -$0.63 per share against an estimate of -$0.4029
  8. Q2 FY26: reported -$0.40 per share against an estimate of -$0.4624

ANVS news

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseGlobe Newswire

    The Credibility Filter Wall Street Uses to Sort Biotech Winners

  • Press releaseGlobe Newswire

    Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releaseGlobe Newswire

    Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

  • Press releaseGlobe Newswire

    Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

  • Press releaseGlobe Newswire

    Annovis to Host Webinar and Live Q&A on June 24, 2025

Similar companies

Companies in the same industry as Annovis Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.